Research ArticleBasic Science Investigation
Radioimmunotherapy for the Intensification of Conditioning Before Stem Cell Transplantation: Differences in Dosimetry and Biokinetics of 188Re- and 99mTc-Labeled Anti-NCA-95 MAbs
Jörg Kotzerke, Gerhard Glatting, Ulrike Seitz, Marion Rentschler, Bernd Neumaier, Donald Bunjes, Christian Duncker, Dagmar Dohr, Lothar Bergmann and Sven N. Reske
Journal of Nuclear Medicine March 2000, 41 (3) 531-537;
Jörg Kotzerke
Gerhard Glatting
Ulrike Seitz
Marion Rentschler
Bernd Neumaier
Donald Bunjes
Christian Duncker
Dagmar Dohr
Lothar Bergmann
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Radioimmunotherapy for the Intensification of Conditioning Before Stem Cell Transplantation: Differences in Dosimetry and Biokinetics of 188Re- and 99mTc-Labeled Anti-NCA-95 MAbs
Jörg Kotzerke, Gerhard Glatting, Ulrike Seitz, Marion Rentschler, Bernd Neumaier, Donald Bunjes, Christian Duncker, Dagmar Dohr, Lothar Bergmann, Sven N. Reske
Journal of Nuclear Medicine Mar 2000, 41 (3) 531-537;
Radioimmunotherapy for the Intensification of Conditioning Before Stem Cell Transplantation: Differences in Dosimetry and Biokinetics of 188Re- and 99mTc-Labeled Anti-NCA-95 MAbs
Jörg Kotzerke, Gerhard Glatting, Ulrike Seitz, Marion Rentschler, Bernd Neumaier, Donald Bunjes, Christian Duncker, Dagmar Dohr, Lothar Bergmann, Sven N. Reske
Journal of Nuclear Medicine Mar 2000, 41 (3) 531-537;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Auger Electron Radioimmunotherapeutic Agent Specific for the CD123+/CD131- Phenotype of the Leukemia Stem Cell Population
- Anti-CD45 Monoclonal Antibody YAML568: A Promising Radioimmunoconjugate for Targeted Therapy of Acute Leukemia
- Bone Marrow Transplantation Nephropathy after an Intensified Conditioning Regimen with Radioimmunotherapy and Allogeneic Stem Cell Transplantation
- Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study
- How Far Have We Come with Solid (Nonhematologic) Tumor Radioimmunotherapy?